This is a working overview of PT-141, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-05-26. Anything still debated is marked as such rather than presented as settled.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
| Property | Value | Notes |
|---|---|---|
| Primary receptor target | MC4 melanocortin receptor | Other melanocortin subtypes are also activated |
| Typical route in approved use | Subcutaneous injection | Single-use format in the marketed product |
| Elimination half-life | Roughly two to three hours | Short exposure supports as-needed use |
| Common adverse events | Nausea, flushing, headache | Generally transient but can be dose limiting |
| Main studied group | Premenopausal women with low desire | Controlled data outside this group are limited |
Lyophilised peptide is generally held below minus twenty degrees Celsius, protected from light and moisture, because hydrolysis and oxidation accumulate faster at ambient temperature. Once reconstituted, solutions are typically kept between two and eight degrees Celsius and used within a short window defined by the supplier. Repeated freeze-thaw cycles are avoided since they promote aggregation and loss of soluble material. Container material matters as well, because peptides adsorb to certain plastics and glass surfaces at low concentration. Stability figures supplied by a vendor apply only to the specific lot and buffer that were tested.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography combined with mass spectrometry. A gradient of water and acetonitrile containing trifluoroacetic acid is a common mobile phase, and ultraviolet detection near 214 nanometres responds to the peptide backbone. Mass spectrometry confirms the expected molecular mass and helps reveal truncation or oxidation products. Purity is reported as a peak-area percentage, a figure that depends on the wavelength and gradient used, so values from different laboratories are not always directly comparable. Peptide mapping and amino acid analysis provide additional confirmation when required.
Regulatory status varies by jurisdiction, where approved prescription products, compounded preparations and research-grade material are treated as distinct categories with different documentation requirements. Suppliers of research material commonly issue a certificate of analysis listing purity, identity and sometimes endotoxin content. Independent verification by a third-party laboratory is often recommended because self-reported figures are difficult to check. Literature discussions usually state the source, purity and storage conditions of the material used, since these details affect reproducibility. Analysts note that a reported purity figure does not by itself describe biological activity.
Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
From a pharmacokinetic standpoint, the peptide is usually delivered by injection because oral bioavailability is very low; proteases in the digestive tract degrade it rapidly. After subcutaneous administration, plasma concentrations reach a peak within roughly one hour. Its elimination half-life is relatively short, with most reports placing it in the range of a few hours. Nasal formulations have also been examined, though absorption varies widely between individuals. Metabolism proceeds mainly through peptidase cleavage, and the resulting products are excreted by the kidneys.
structural formula A graphical representation of the molecular structure and geometry of a particular chemical compound, showing how the atoms are arranged in real, three-dimensional space. Chemical bonding within the molecule is also shown, either implicitly or explicitly. When known with certainty, structural formulas are very useful because they allow chemists to visualize the molecules and the structural changes that occur in them during chemical reactions.
{\displaystyle {\begin{aligned}K_{M}\ &{\stackrel {\mathrm {def} }{=}}\ {\frac {k_{2}+k_{-1}}{k_{1}}}\approx K_{D}\\V_{\max }\ &{\stackrel {\mathrm {def} }{=}}\ k_{cat}{\ce {[E]}}_{tot}\end{aligned}}}
Hydrogen thus forms a covalent H2 molecule, and boron forms a giant covalent structure based on icosahedral B12 clusters. In a metal, the bonding and antibonding orbitals have overlapping energies, creating a single band that electrons can freely flow through, allowing for electrical conduction.
Sources: en.wikipedia.org
Worldwide: alcohol (beer, wine), vinegar, olives, yogurt, bread, cheese Asia East and Southeast Asia: amazake, atchara, belacan, burong mangga, com ruou, doenjang, douchi, fish sauce, lah pet, lambanog, kimchi, kombucha, leppet-so, narezushi, miso, nata de coco, nattō, ngapi, oncom, padaek, pla ra, prahok, ruou nep, sake, shrimp paste, soju, soy sauce, stinky tofu, tape, tempeh, tempoyak, zha cai Central Asia: kumis, kefir, shubat, qatiq (yogurt) South Asia: achar, appam, dosa, dhokla, dahi (yogurt), idli, mixed pickle, ngari, sinki, tongba, paneer Africa: garri, injera, laxoox, mageu, ogi, ogiri, iru Americas: chicha, chocolate, vanilla, hot sauce, tepache, tibicos, pulque, muktuk, kiviak, parakari Middle East: torshi, boza Europe: sourdough bread, elderberry wine, kombucha, pickling, rakfisk, sauerkraut, pickled cucumber, surströmming, mead, kvass, salami, sucuk, prosciutto, cultured milk products such as quark, kefir, filmjölk, crème fraîche, smetana, skyr, rakı, tupí, żur. Oceania: poi, kānga pirau
=== Angevin transition === After the Polish royal line and Piast junior branch died out in 1370, Poland came under the rule of Louis I of Hungary of the Capetian House of Anjou, who presided over a union of Hungary and Poland that lasted until 1382. In 1374, Louis granted the Polish nobility the Privilege of Koszyce to assure the succession of one of his daughters in Poland. His youngest daughter Jadwiga (d. 1399) assumed the Polish throne in 1384.
For diabatically enhanced classical events, at 24 hours prior to the onset of CAD, a prominent 250-mb jet extends from southwest to northeast across eastern North America. A general area of troughing is present at the 500- and 250-mb levels west of the jet. The parent high-pressure system is centered over the upper Midwest beneath the 250-mb jet entrance region, setting up conditions for CAD east of the Rocky Mountains. For dry onset classical events, the 250-mb jet is weaker and centered farther east relative to the diabatically enhanced classical events. The jet also does not extend as far southwest compared to diabatically enhanced classical CAD events. The center of the high-pressure system is farther east, so ridging extends southward into the south-central eastern United States. Although both types of classical events begin differently, their results are very similar.
Sources: en.wikipedia.org
Acute toxicity has been reportedly associated with hyperhidrosis, panic attacks, severe anxiety, mydriasis, paranoia, aggressive behavior, psychosis, rhabdomyolysis, and punding. The violent and aggressive behavior associated with acute stimulant toxicity may partially be driven by paranoia. Most drugs classified as stimulants are sympathomimetic, meaning that they stimulate the sympathetic branch of the autonomic nervous system. This stimulation leads to effects such as mydriasis (dilation of the pupils), increased heart rate, blood pressure, respiratory rate and body temperature. When these changes become pathological, they are called arrhythmia, hypertension, and hyperthermia, and may lead to rhabdomyolysis, stroke, cardiac arrest, or seizures. However, given the complexity of the mechanisms that underlie these potentially fatal outcomes of acute stimulant toxicity, it is impossible to determine what dose may be lethal.
Isabel Kershner; British-born Israeli journalist and author, who began reporting from Jerusalem for The New York Times; has worked as senior Middle East editor for The Jerusalem Report magazine; also written for The New Republic and has provided commentary on Middle East affairs on BBC Radio; latest book is "The Land of Hope and Fear: Israel's Battle for its Inner Soul"; married to South African born Israeli author Hirsh Goodman, an employee of the Institute for National Security Studies, which is involved in promoting a positive image of Israel, and which Kershner often relies on as a source. Ian Katz (born 9 February 1968) of South African Jewish origin; journalist and broadcasting executive currently Chief Content Officer at Channel 4, overseeing all editorial decision making and commissioning across Channel 4's linear channels, streaming services and social media. Katz originally followed a career in print journalism, and was a deputy editor of The Guardian until 2013. He then became the editor of the Newsnight current affairs programme on BBC Two, a role which he left in late 2017 to join Channel 4. Mike Katz, chair of the Jewish Labour Movement; journalist for Jewish News, The Jewish Chronicle, Times of Israel, The Guardian, Forbes, Harvard Business Review, The Business Journals, HuffPost UK, New Statesman, LabourList, Camden New Journal, writing mainly on the theory of 'the new anti-Semitism' in Jeremy Corbyn's Labour Party and the demise of his leadership.
Ambulatory care pharmacy (BCACP) Critical care pharmacy (BCCCP) Nuclear pharmacy (BCNP) Nutrition support pharmacy (BCNSP) Oncology pharmacy (BCOP) Pediatric pharmacy (BCPPS) Geriatric pharmacy (BCGP) Pharmacotherapy (BCPS) Infectious disease pharmacy (BCIDP) Compounded sterile preparations pharmacy (BCSCP) Cardiology pharmacy (BCCP) Emergency medicine pharmacy (BCEMP) Transplant Pharmacist (BCTXP) Psychiatric pharmacy (BCPP) There are several types of clinical pharmacists in the United States. In California they are called advanced practice pharmacists (APh). In New Mexico, they are known as Pharmacist Clinicians (PhC) and lastly in Montana and North Carolina they are known as Clinical Pharmacist Practitioners (CPP). Clinical pharmacists in the Veteran Administration are known as Clinical Pharmacy Specialists (CPS). Role in the health care system Within the system of health care, clinical pharmacists are experts in the therapeutic use of medications. They routinely provide medication therapy evaluations and recommendations to patients and other health care professionals. Clinical pharmacists are a primary source of scientifically valid information and advice regarding the safe, appropriate, and cost-effective use of medications. Clinical pharmacists are also making themselves more readily available to the public. In the past, access to a clinical pharmacist was limited to hospitals, clinics, or educational institutions.
Sources: en.wikipedia.org
The approved formulation is given by subcutaneous injection and is used on an as-needed basis rather than on a fixed daily schedule. An intranasal version was studied earlier but did not reach the same stage of development. Route of delivery strongly affects how quickly the peptide appears in circulation.
It means the product is taken shortly before anticipated activity instead of every day. This pattern reduces total exposure and shapes how safety monitoring is planned. It also means effects are expected to be temporary rather than cumulative.
Desire is assessed through validated self-report questionnaires, sometimes paired with event counts and a distress scale. These instruments capture subjective experience, so results depend on how participants interpret the questions. No laboratory marker currently substitutes for such reporting.
PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.